National Guideline Clearinghouse | Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy.

full-text ►

National Guideline Clearinghouse | Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy.



National Institute for Health and Care Excellence (NICE)

February 24, 2014

Guideline Title

Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Aug. 62 p. (Technology appraisal guidance; no. 295).

Guideline Status

This is the current release of the guideline.